Венорутон®

General characteristics. Structure:

Akitivny substance: 1 capsule contains About - (beta hydroxyethyl) of rutosides (okserutin) of 300 mg;

Excipients: polyethyleneglycol 6000, gelatin, titanium dioxide, gland dioxide.

Pharmacological properties:

Drug has angioprotektorny and flebotoniziruyushchy effect. Derivative routine. Affects preferential capillaries and veins.
 
Narrows pores between endothelial cells due to modification of the fibrous matrix located between endothelium cells. Inhibits aggregation and increases degree of deformability of erythrocytes. Has antiinflammatory effect.

At chronic venous insufficiency of Venoruton® reduces expressiveness of its such manifestations as hypostases, pain, spasms, trophic frustration, varicose ulcers. Reduces the symptoms connected with hemorrhoids including pain, an itch and bleeding.
 
Making favorable impact on permeability and resistance of walls of capillaries, drug promotes delay of development of a diabetic retinopathy. Thanks to influence of rutoside on rheological properties of blood, drug promotes prevention of microthromboses of a retina.

Pharmacokinetics

Absorption and distribution
 
After intake absorption makes about 10-15%. Cmax in a blood plasma is reached within 1-9 h. During 120 h concentration remain defined; their decrease happens bieksponentsialno.
 
Removal
 
T1/2 makes 10-25 h O-(β-гидроксиэтил) - rutosides and their glucuronic metabolites are removed generally with bile, 3-6% are removed by kidneys for 48 h.

Indications to use:

- chronic venous insufficiency;
- postflebitichesky syndrome;
- trophic disturbances at a varicosis;
- trophic ulcers;
- as auxiliary treatment at a lymphostasis after performing sclerosing therapy and removal of varicose nodes;
- hemorrhoids (pain, exudation, itch and bleeding);
- venous insufficiency and hemorrhoids at pregnancy, since the II trimester;
- as auxiliary treatment of a retinopathy at patients with a diabetes mellitus, at arterial hypertension and atherosclerosis.

Route of administration and doses:

Inside appoint in an initiation of treatment 300 mg (1 capsule) of 3 times/days during food. Reduction of expressiveness of symptoms is usually noted within 2 weeks of treatment. It is recommended to continue administration of drug in the same dose or reduce 600 mg/days to the minimum maintenance dose, or stop treatment. At the same time the reached effect remains for 4 weeks.

Capsules are swallowed entirely, washing down with enough water.
 
At a lymphostasis the recommended dose makes 3 g/days.

At a diabetic retinopathy appoint 0.9-1.8 g/days.

Features of use:

If at drug use expressiveness of symptoms of a disease does not decrease, recommended to verify the diagnosis.

Side effects:

From the alimentary system: nausea, diarrhea, heartburn.
 
Allergic reactions: skin rash.
 
Others: a headache, rushes of blood to the person.
 
Side effects quickly disappear after drug phase-out.

Interaction with other medicines:

Action of Venorutonum amplifies at simultaneous use with ascorbic acid.

Contraindications:

- hypersensitivity to rutosides or other components of drug;
- I trimester of pregnancy.

Pregnancy and lactation

During clinical trials use of Venorutonum at pregnancy was studied, however, its use in the I trimester specially was not studied.
 
In the researches conducted on animals teratogenic and other undesirable impact of drug on a fruit was not noted.

It is inside recommended to appoint Venoruton®, only since the II trimester of pregnancy when the expected advantage for mother of its use exceeds possible risk for a fruit.

Overdose:

About overdose cases which would be followed by clinical symptoms, it was not reported.

Storage conditions:

List B. Drug should be stored in the place, dry, unavailable to children, at a temperature not above 30 °C. A period of validity - 3 years.

Issue conditions:

Without recipe

Packaging:

Capsules of 300 mg; packaging planimetric cell 10